Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Key Stats

• Today's Range: $21.35 to $22.27
• 50-Day Range: $19.53 to $23.96
• 52-Week Range: $13.49 to $24.64
• Volume: 918,453 shs
• Average Volume: 856,122 shs
• Market Capitalization: $2.58 billion
• P/E Ratio: 18.33
• Dividend Yield: N/A
• Price Target: $32.25
• Consensus Rating: Buy

Catalyst Pharmaceuticals Stock Analysis - MarketRank™

Catalyst Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 26th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Catalyst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.11%

Earnings Growth

Earnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Catalyst Pharmaceuticals is 18.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Catalyst Pharmaceuticals is 18.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 18.26.

Price to Earnings Growth Ratio

Catalyst Pharmaceuticals has a PEG Ratio of 3.31. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Catalyst Pharmaceuticals has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.49% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Catalyst Pharmaceuticals has recently decreased by 19.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Catalyst Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Catalyst Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.99

Percentage of Shares Shorted

4.49% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Catalyst Pharmaceuticals has recently decreased by 19.31%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.65

News Sentiment

Catalyst Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

29 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 107% compared to the previous 30 days.

MarketBeat Follows

10 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,754,140.00 in company stock.

Percentage Held by Insiders

11.00% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CPRX Stock Analysis - Frequently Asked Questions

How have CPRX shares performed this year?

Catalyst Pharmaceuticals' stock was trading at $20.87 on January 1st, 2025. Since then, CPRX shares have increased by 3.6% and is now trading at $21.6260.
View the best growth stocks for 2025 here.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 40.79% and a net margin of 31.01%.

Who are Catalyst Pharmaceuticals' major shareholders?

Top institutional shareholders of Catalyst Pharmaceuticals include Vanguard Group Inc. (7.07%), Deerfield Management Company L.P. Series C (2.63%), Dimensional Fund Advisors LP (2.53%) and Pacer Advisors Inc. (2.48%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Richard J Daly, Philip H Coelho, Brian Elsbernd, Gary Ingenito, Alicia Grande, Carmen Jeffrey Del, Preethi Sundaram and Molly Harper.
View institutional ownership trends.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 2/22/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CPRX
• CUSIP: N/A
• CIK: 1369568
• Web: www.catalystpharma.com
• Phone: (305) 420-3200
• Fax: 305-529-0933
• Employees: 80
• Year Founded: 2002

Price Target and Rating

• Average Stock Price Target: $32.25
• High Stock Price Target: $36.00
• Low Stock Price Target: $28.00
• Potential Upside/Downside: +49.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.18
• Trailing P/E Ratio: 18.33
• Forward P/E Ratio: 11.38
• P/E Growth: 3.38
• Net Income: $71.41 million
• Net Margins: 31.01%
• Pretax Margin: 41.00%
• Return on Equity: 40.79%
• Return on Assets: 34.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.11
• Quick Ratio: 4.92

Sales & Book Value

• Annual Sales: $398.20 million
• Price / Sales: 6.48
• Cash Flow: $1.97 per share
• Price / Cash Flow: 10.95
• Book Value: $3.30 per share
• Price / Book: 6.55

Miscellaneous

• Outstanding Shares: 119,270,000
• Free Float: 106,153,000
• Market Cap: $2.58 billion
• Optionable: Optionable
• Beta: 0.80